Evidence map›Paper›PMID 35743312›Full record

ArticleInternational journal of molecular sciences2022

In Vivo Inhibition of TRPC6 by SH045 Attenuates Renal Fibrosis in a New Zealand Obese (NZO) Mouse Model of Metabolic Syndrome.

Zhihuang Zheng, Yao Xu, Ute Krügel, Michael Schaefer, Tilman Grune, Bernd Nürnberg, May-Britt Köhler, Maik Gollasch, Dmitry Tsvetkov, Lajos Markó

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Roles of TRP and PIEZO receptors in autoimmune diseases.Expert reviews in molecular medicine · 2024
    Review
  7. Article
  8. Article
  9. Proximal TubularInternational journal of molecular sciences · 2023
    Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Zhihuang ZhengDepartment of Nephrology/Intensive Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.ORCID 0000-0002-5114-3824
Yao XuDepartment of Internal Medicine and Geriatrics, University Medicine Greifswald, 17475 Greifswald, Germany.
Ute KrügelRudolf Boehm Institute for Pharmacology and Toxicology, Leipzig University, 04107 Leipzig, Germany.ORCID 0000-0002-2317-2302
Michael SchaeferRudolf Boehm Institute for Pharmacology and Toxicology, Leipzig University, 04107 Leipzig, Germany.
Tilman GruneDepartment of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), 14558 Nuthetal, Germany.
Bernd NürnbergDepartment of Pharmacology, Experimental Therapy and Toxicology and Interfaculty Center of Pharmacogenomics and Drug Research, University of Tübingen, 72076 Tübingen, Germany.ORCID 0000-0002-5995-6555
May-Britt KöhlerExperimental and Clinical Research Center, a Joint Cooperation of the Charité-University Medicine Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
Maik GollaschDepartment of Nephrology/Intensive Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
Dmitry TsvetkovDepartment of Internal Medicine and Geriatrics, University Medicine Greifswald, 17475 Greifswald, Germany.
Lajos MarkóExperimental and Clinical Research Center, a Joint Cooperation of the Charité-University Medicine Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
Max Delbrück Center · DEUniversitätsmedizin Greifswald · DELeipzig University · DEGerman Centre for Cardiovascular Research · DEUniversity of Tübingen · DE

Funding

Deutsche Forschungsgemeinschaft GO766/18-2, GO 766/12-3, SFB 1365, NU 53/12-2, TRR 152This work was supported by the Deutsche Forschungsgemeinschaft (DFG) to M.G. (GO766/18-2, GO 766/12-3, SFB 1365), B.N. (NU 53/12-2) and M.S. (TRR 152) and Dr. Werner Jackstädt-Stiftung. GO766/18-2, GO 766/12-3, SFB 1365, NU 53/12-2, TRR 152
6 · The paper itself

Abstract

Metabolic syndrome is a significant worldwide public health challenge and is inextricably linked to adverse renal and cardiovascular outcomes. The inhibition of the transient receptor potential cation channel subfamily C member 6 (TRPC6) has been found to ameliorate renal outcomes in the unilateral ureteral obstruction (UUO) of accelerated renal fibrosis. Therefore, the pharmacological inhibition of TPRC6 could be a promising therapeutic intervention in the progressive tubulo-interstitial fibrosis in hypertension and metabolic syndrome. In the present study, we hypothesized that the novel selective TRPC6 inhibitor SH045 (larixyl N-methylcarbamate) ameliorates UUO-accelerated renal fibrosis in a New Zealand obese (NZO) mouse model, which is a polygenic model of metabolic syndrome. The in vivo inhibition of TRPC6 by SH045 markedly decreased the mRNA expression of pro-fibrotic markers (

Indexed as

HypertensionKidney DiseasesMetabolic SyndromeUreteral ObstructionAnimalsDisease Models, AnimalFibrosisKidneyMiceMice, ObeseNew ZealandObesityTRPC6 Cation ChannelTRPC6 Cation ChannelTrpc6 protein, mouseCKDfibrosisinflammationNZO miceSH045TRPC6UUO

Identifiers

PMID35743312
PMCPMC9224794
OpenAlexW4283215130

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.